1 |
sofosbuvir/ledipasvir
(32 times)
|
Gastroenterology (8 times)
|
HCV (20 times) SVR (9 times) RBV (7 times)
|
2015 Perspectives of fixed daily dose of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C.
|
2 |
safety of sofosbuvir/ledipasvir
(2 times)
|
Medicine (1 time)
|
AEs (1 time) CI (1 time) CKD (1 time)
|
2018 Effectiveness, treatment completion and safety of sofosbuvir/ledipasvir and paritaprevir/ritonavir/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES study.
|
3 |
safety of generic sofosbuvir/ledipasvir
(1 time)
|
Internal Medicine (1 time)
|
DAA (1 time) HCV (1 time) IFN (1 time)
|
2020 Real-life efficacy of generic sofosbuvir/ledipasvir for treatment of Iranian patients with chronic hepatitis C: A cohort study.
|
4 |
SOF/ledipasvir
(1 time)
|
Gastroenterology (1 time)
|
DAAs (1 time) GEPCOI (1 time) RBV (1 time)
|
2020 Chronic hepatitis C treatment in HIV co-infection in Portugal: Results from a cohort OF 2133 patients presented by GEPCOI (Portuguese Coinfection Study Group).
|